Business
Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings
-Presentations at five upcoming scientific meetings will focus on the broad therapeutic applications of Avidity's AOC platform- SAN DIEGO, Sept. 14, 2020
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"-Presentations at five upcoming scientific meetings will focus on the broad therapeutic applications of Avidity's AOC platform-\n\n\nSAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will present at several upcoming virtual scientific meetings.\nTIDES USA 2020 (Sept. 15th - 18th) Session Chair Date: Wednesday, September 16th, 3:45 PM – 4:30 PM, ET\n16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 2020 (Sept. 27th - 30th) Title: Recent Progress with Antibody Oligonucleotide Conjugates Date: Monday, September 28th, 12:45 PM – 1:10 PM, ET\nNext Generation Protein Therapeutics & Bioconjugates Summit 2020 (Nov. 2nd - 5th) Title: Oligonucleotide Therapeutics: Now on Target with Antibody Conjugates Date: Thursday, November 5th, 9:40 AM – 10:00 AM, ET\nTIDES Europe: Oligonucleotide and Peptide Therapeutics (Nov. 11th - 13th) Keynote Address: Recent Advances with Antibody-siRNA Conjugates Date: Friday, November 13th, 2:45PM – 3:30 PM, CET\n3rd Annual Neuromuscular Drug Development Summit (Dec. 1st - 3rd) Title: Pioneering a New Class of Oligonucleotide Therapies: Developing an Oligonucleotide Antibody Conjugate for the Treatment of DM1 Date: Thursday, December 3rd, 10:10 AM – 10:30 AM, ET\n\"Presenting at five premier RNA-focused and neuromuscular conferences is an important opportunity to highlight the continued advancement of our novel AOC platform,\" said Art Levin, Chief Scientific Officer. \"We are progressing this research to the clinic as we expect AOC 1001, our first clinical candidate, to enter a Phase 1/2 clinical trial next year in adults with myotonic dystrophy type 1, a serious genetic disease with no available treatment.\" \nAbout Avidity Biosciences\nAvidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undrug...